Biomea Fusion(BMEA) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights SAN CARLOS, Calif., August 5, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "Biomea Fusion" or "the Company") (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the second quarter ended June 30, 2025, and provided a business update. "In the second quarter, we presented clinical and preclinical results with icovamenib that support its unique role a ...